Cargando…
Human blood serum can donor-specifically antagonize effects of EGFR-targeted drugs on squamous carcinoma cell growth
Many patients fail to respond to EGFR-targeted therapeutics, and personalized diagnostics is needed to identify putative responders. We investigated 1630 colorectal and lung squamous carcinomas and 1357 normal lung and colon samples and observed huge variation in EGFR pathway activation in both canc...
Autores principales: | Kamashev, Dmitry, Sorokin, Maksim, Kochergina, Irina, Drobyshev, Aleksey, Vladimirova, Uliana, Zolotovskaia, Marianna, Vorotnikov, Igor, Shaban, Nina, Raevskiy, Mikhail, Kuzmin, Denis, Buzdin, Anton |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7966997/ https://www.ncbi.nlm.nih.gov/pubmed/33748471 http://dx.doi.org/10.1016/j.heliyon.2021.e06394 |
Ejemplares similares
-
Human Blood Serum Can Diminish EGFR-Targeted Inhibition of Squamous Carcinoma Cell Growth through Reactivation of MAPK and EGFR Pathways
por: Kamashev, Dmitri, et al.
Publicado: (2023) -
Human Blood Serum Inhibits Ductal Carcinoma Cells BT474 Growth and Modulates Effect of HER2 Inhibition
por: Kamashev, Dmitrii, et al.
Publicado: (2022) -
DNA repair pathway activation features in follicular and papillary thyroid tumors, interrogated using 95 experimental RNA sequencing profiles
por: Vladimirova, Uliana, et al.
Publicado: (2021) -
Better Agreement of Human Transcriptomic and Proteomic Cancer Expression Data at the Molecular Pathway Activation Level
por: Raevskiy, Mikhail, et al.
Publicado: (2022) -
Mutation Enrichment and Transcriptomic Activation Signatures of 419 Molecular Pathways in Cancer
por: Zolotovskaia, Marianna A., et al.
Publicado: (2020)